Meneveau N, Schiele F, Bouras Y, Mouhat T, Anguenot T, Bernard Y, Bassand J P
Service de cardiologie, CHU Saint-Jacques, Besançon.
Arch Mal Coeur Vaiss. 1995 Jun;88(6):825-31.
Thrombolytic therapy leads to more rapid dissolution of thrombi in severe pulmonary embolism than conventional heparin therapy but is considered with much reserve in elderly patients because of the risk of haemorrhage, which is thought to be potentially greater in these subjects. The object of this study was to assess the efficacy and safety of thrombolytic therapy in patients over 70 years of age with severe pulmonary embolism, compared with patients under 70 years of age with the same condition. Eighty-nine patients with severe pulmonary embolism (Miller score > 17/34) were prescribed thrombolytic therapy in the absence of a contraindication without taking age into consideration. Fifty-three were under 70 years of age (54 +/- 15; range: 18 to 70 years) and 36 were over 70 years of age (78 +/- 5; range: 71 to 88 years). Apart from age, there was no difference in the clinical presentation of the two groups. Thrombolytic therapy was initiated with streptokinase 100,000 IU/hr for twelve hours after an initial bolus of 250,000 IU or with urokinase or plasminogen tissue activator in cases with a contraindication to streptokinase. An uncomplicated course was observed in the same percentage of cases in the two groups. The Miller score and mean pulmonary pressures fell in the same way in the two groups. Three patients died during the hospital period, two aged under 70 (3.7%) and one over 7 years of age (2.7%). Major bleeding occurred in 3 subjects under 70 (5.6%) and 5 subjects over 70 (13.8%) (p = 0.29).(ABSTRACT TRUNCATED AT 250 WORDS)
与传统肝素治疗相比,溶栓治疗能更迅速地溶解严重肺栓塞中的血栓,但由于出血风险,老年患者使用时需格外谨慎,因为老年患者的出血风险可能更高。本研究的目的是评估70岁以上严重肺栓塞患者与70岁以下相同病情患者接受溶栓治疗的疗效和安全性。89例严重肺栓塞患者(米勒评分>17/34)在无禁忌证的情况下接受溶栓治疗,未考虑年龄因素。53例患者年龄在70岁以下(54±15岁;范围:18至70岁),36例患者年龄在70岁以上(78±5岁;范围:71至88岁)。除年龄外,两组的临床表现无差异。溶栓治疗起始剂量为链激酶250,000 IU静脉推注后,以100,000 IU/小时持续输注12小时;对链激酶有禁忌证的患者则使用尿激酶或组织型纤溶酶原激活剂。两组中病情未出现并发症的病例比例相同。两组的米勒评分和平均肺动脉压下降情况相同。住院期间有3例患者死亡,2例年龄在70岁以下(3.7%),1例年龄在70岁以上(2.7%)。70岁以下有3例(5.6%)、70岁以上有5例(13.8%)发生大出血(p = 0.29)。(摘要截选至250字)